Approval · Notice of Compliance 35547 · 2025
OPDIVO: Notice of Compliance 35547
Issued June 19, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35547
- Date
- June 19, 2025
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication: in combination with ipilimumab, the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OPDIVO | Not yet assigned | — |